poisar

Stocks · News reference

Summit Therapeutics Initiates Phase III HARMONi-10 Clinical Trial for Ivonescimab

Fiscal.ai

Summit Therapeutics has launched the HARMONi-10 global Phase III clinical trial to evaluate ivonescimab as a consolidation therapy for patients with unresectable Stage III non-small cell lung cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolTmf Breakfast News

    Breakfast News: Summit’s FDA Setback Isn’t the End

    Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.